RECEPTORAI Showcases AI-Driven Peptide Permeability Approach at Drug Discovery Meeting

According to a recent LinkedIn post from RECEPTORAI, CEO and founder Dr. Alan Nafiev recently spoke at the Drug Discovery Chemistry conference in San Diego. The post indicates that the company presented data on how its platform can improve both affinity and permeability for a 16‑mer peptide by optimizing these properties simultaneously.

The LinkedIn post suggests that RECEPTORAI’s methods support the design of membrane‑permeable and GI‑permeable peptides by accounting for chameleonic features, permeability‑relevant conformational states, and membrane‑associated behavior in different environments. This focus may position the company to address a key challenge in peptide drug development, potentially increasing the attractiveness of its technology to biopharma partners.

By emphasizing work at the intersection of AI, computational chemistry, and peptide drug discovery, the post points to RECEPTORAI’s strategic orientation toward advanced, data‑driven discovery tools. For investors, participation in a specialized conference and engagement with industry peers could signal efforts to build scientific credibility and expand collaborative opportunities, which may be important drivers of future deal flow and revenue.